On 11 April 2005, orphan designation (EU/3/05/270 was granted by the European Commission to Antigenics Therapeutics Limited, Ireland, for autologous tumor derived gp96 heat shock proteinpeptide complex for the treatment of renal cell carcinoma.
Autologous Tumor-Derived gp96 Heat Shock Protein-Peptide Complex
Treatment of renal-cell carcinoma
|Orphan designation status||
|EU designation number||
|Date of designation||
Antigenics Therapeutics Limited
25/28 North Wall Quay
Telephone: +353 1 649 2000
Telefax: +353 1 649 2649
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: